Abstract
Aim: The aim of this study is to curb the spread of COVID-19, India, has provided the Made-in-India AstraZeneca vaccine to Bangladesh. This research article will try to explain the AstraZeneca COVID-19 vaccine experience among Bangladeshi citizens. Methodology: The article is based on a qualitative research design and the authors have reviewed the related review of literature on the postvaccine experience and the efficacy of COVID-19 vaccines. Results: Through review-based literature, it was found that many Bangladeshi citizens including comorbid patients have not suffered any adverse events from the COVID-19 vaccines. Adverse events usually appeared after 12 h and went away within 48 h of vaccination. Most of the Bangladeshi population was satisfied during and after the vaccination program and most of them are recommending the COVID-19 vaccines to others as well. Conclusion: India constantly supplied COVID-19 vaccine assistance to Bangladesh and no adverse events from the vaccine were observed among the people.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Asian Journal of Pharmaceutical Research and Health Care
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
